Phase 1 × Completed × Lymphoma, B-Cell, Marginal Zone × Clear all
NCT02996773 2025-11-10

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

University of Arizona

Phase 1 Completed
50 enrolled
NCT02924402 2024-11-13

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Xencor, Inc.

Phase 1 Completed
154 enrolled
NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Celldex Therapeutics

Phase 1 Completed
132 enrolled
NCT03833180 2024-01-12

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Completed
91 enrolled
NCT01523223 2023-11-22

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Stanford University

Phase 1 Completed
16 enrolled
NCT00443976 2023-08-04

Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma

Canadian Cancer Trials Group

Phase 1 Completed
35 enrolled
NCT00054236 2020-07-27

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Case Comprehensive Cancer Center

Phase 1 Completed
55 enrolled
NCT01094860 2020-02-11

Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
29 enrolled
NCT00036790 2019-12-17

Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer

University of Wisconsin, Madison

Phase 1 Completed
NCT00049712 2019-12-13

Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma

University of Wisconsin, Madison

Phase 1 Completed
NCT00005946 2019-10-17

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

University of Maryland, Baltimore

Phase 1 Completed
NCT00392691 2019-05-15

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Swiss Cancer Institute

Phase 1 Completed
20 enrolled
NCT00005639 2019-01-11

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
34 enrolled
NCT01484015 2018-07-18

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Wake Forest University Health Sciences

Phase 1 Completed
70 enrolled
NCT01129193 2018-06-04

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
44 enrolled
NCT01567709 2018-04-11

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
34 enrolled
NCT00889408 2017-12-02

DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
25 enrolled
NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

National Cancer Institute (NCI)

Phase 1 Completed
17 enrolled
NCT00104923 2017-07-19

Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer

California Cancer Consortium

Phase 1 Completed
29 enrolled
NCT00513474 2017-05-25

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Massachusetts General Hospital

Phase 1 Completed
46 enrolled 11 charts
NCT00509691 2017-05-09

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

University of Louisville

Phase 1 Completed
20 enrolled
NCT00047164 2016-09-26

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
89 enrolled
NCT00293488 2016-06-23

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

Progen Pharmaceuticals

Phase 1 Completed
20 enrolled
NCT00082823 2016-06-03

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Regeneron Pharmaceuticals

Phase 1 Completed
25 enrolled
NCT00083213 2016-06-03

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Regeneron Pharmaceuticals

Phase 1 Completed
25 enrolled
NCT01748721 2016-01-08

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Morphotek

Phase 1 Completed
27 enrolled